SCHEMBL433676

SCHEMBL433676

COC(=O)CC(=O)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.65
NR4A1 P22736 1/20 0.64
NR4A2 P43354 1/20 0.64
NR4A3 Q92570 1/20 0.64
EGFR P00533 2/20 0.62
L3MBTL1 Q9Y468 2/20 0.61
PARP10 Q53GL7 1/20 0.60
SMN1; SMN2 Q16637 8/20 0.59
RAB9A P51151 7/20 0.59
ALDH1A1 P00352 4/20 0.59
MAPT P10636 2/20 0.59
HTT P42858 2/20 0.59
GAA P10253 1/20 0.59
SRD5A2 P31213 1/20 0.59
NPC1 O15118 6/20 0.58
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
HDAC3 O15379 1/20 0.57
HDAC1 Q13547 1/20 0.57
HDAC2 Q92769 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL377079 0.87 MAOB (0.60) MAOBNR4A1NR4A2NR4A3EGFR
SCHEMBL12987281 0.86 MAOB (0.71) MAOBNR4A1NR4A2NR4A3EGFR
SCHEMBL4709350 0.86 HDAC3 (0.59) MAOBNR4A1NR4A2NR4A3EGFR
SCHEMBL9718167 0.86 NR4A1 (0.70) MAOBNR4A1NR4A2NR4A3EGFR
SCHEMBL7531827 0.84 PTPN1 (0.73) MAOBNR4A2SRD5A2MEN1KMT2A
SCHEMBL10797162 0.83 MAOB (0.67) MAOBNR4A1NR4A2NR4A3EGFR
SCHEMBL11683646 0.83 PTPN1 (0.72) MAOBNR4A1NR4A2NR4A3EGFR
SCHEMBL435065 0.83 FFAR1 (0.64) MAOBNR4A1NR4A2NR4A3EGFR
SCHEMBL435066 0.83 FFAR1 (0.64) MAOBNR4A1NR4A2NR4A3EGFR
SCHEMBL102983 0.83 RAB9A (0.83) MAOBNR4A1NR4A2NR4A3EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2595952-B1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2020-11-18 EP disclosed
EP-2595952-B1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2020-11-18 EP disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-8889711-B2 Pyrazolopyridine derivatives as anticancer agent PIERRE FABRE MEDICAMENT (FR) 2014-11-18 US disclosed
EP-2289868-B1 CARBOXYLIC ACID COMPOUND DAIICHI SANKYO CO LTD (JP) 2014-08-13 EP disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
EP-2595952-A1 AGONISTS OF GPR40 Connexios Life Sciences Pvt. Ltd. (IN) 2013-05-29 EP disclosed
US-20120245170-A1 PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT PIERRE FABRE MEDICAMENT (FR) 2012-09-27 US disclosed
US-8222281-B2 Carboxylic acid compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-07-17 US disclosed
WO-2012011125-A1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) 2012-01-26 WO disclosed
CN-102076650-A Carboxylic acid compound DAIICHI SANKYO CO LTD 2011-05-25 CN disclosed
US-20110053974-A1 CARBOXYLIC ACID COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-03-03 US disclosed
EP-2289868-A1 CARBOXYLIC ACID COMPOUND Daiichi Sankyo Company, Limited (JP) 2011-03-02 EP disclosed
US-20070112037-A1 Pyrazole Derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2007-05-17 US disclosed
US-7183306-B2 Pyrazole derivatives ASTELLAS PHARMA INC. (JP) 2007-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053974-A1 CARBOXYLIC ACID COMPOUND AKR1C3, SLC5A1, GPR119 MAOB 904/4885NR4A1 1060/4885NR4A2 1764/4885
US-20130237571-A1 AGONISTS OF GPR40 GPR65, GPR55, GPR68 MAOB 2832/4885NR4A1 152/4885NR4A2 74/4885
US-20070112037-A1 Pyrazole Derivatives CYP11B2, CYP11B1, CYP3A43 MAOB 601/4885NR4A1 87/4885NR4A2 428/4885
US-20120245170-A1 PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT DPYD, TYMP, ABCB1 MAOB 2222/4885NR4A1 4169/4885NR4A2 3518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.